Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Yet one of oncology's greatest challenges, Glioblastoma, remains largely unsolved.
-
Eli Lilly's (NYSE:LLY) strong Phase 3 results for Retevmo places the oncology community in the spotlight
-
Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. $NTHI, $ORKA, $ABVX, $SYRE
-
BRISTOL, Tenn., May 28, 2026 (GLOBE NEWSWIRE) -- The Vanderbilt Report today issues market commentary on NextTrip, Inc. (NASDAQ: NTRP), the content-to-commerce travel platform whose preliminary...
-
Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.
-
BRISTOL, Tenn., May 26, 2026 (GLOBE NEWSWIRE) -- The Vanderbilt Report issues positive commentary on SecureTech Innovations, Inc. (OTCQB: SCTH) following the Company’s May 15, 2026 Form 10-Q. In our...
-
BRISTOL, Tenn., May 26, 2026 (GLOBE NEWSWIRE) -- The Vanderbilt Report is issuing positive commentary on Z Squared Inc. (NASDAQ: ZSQR) following the Company's May 15, 2026 Form 10-Q. In our view,...
-
Biotechs continue attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy pla
-
The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare $HCWB, $TGNT, $MRNA, $REGN
-
The U.S. housing and construction sector may be entering its next major consolidation cycle